ACA
SYRE icon

Avoro Capital Advisors’s Spyre Therapeutics SYRE Stock Holding History

Avoro Capital Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-598,600
Closed -$17.6M – 43
2024
Q3 		$17.6M Sell
598,600
-1,240,538
-67% -$34.5M 0.26% 33
2024
Q2 		$43.2M Hold
1,839,138
– – 0.58% 29
2024
Q1 		$69.8M Hold
1,839,138
– – 0.81% 26
2023
Q4 		$39.6M Buy
1,839,138
+1,827,680
+15,951% +$25.2M 0.55% 25
2023
Q3 		$140K Hold
11,458
– – ﹤0.01% 46
2023
Q2 		$129K Buy
+11,458
New +$54.3K ﹤0.01% 43

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Avoro Capital Advisors's SYRE Position: Q4 2024 in Review

Avoro Capital Advisors sold out of Spyre Therapeutics (SYRE) in Q4 2024, closing a stake of 598,600 shares — an estimated $17.6M sold.

Avoro Capital Advisors first reported a position in SYRE in Q2 2023 and held it in 6 quarters. The position peaked at $69.8M in Q1 2024. 131 funds tracked by Wall St. Rank hold SYRE as of Q4 2024.

  • Avoro Capital Advisors reported no remaining Spyre Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Avoro Capital Advisors sold 598,600 Spyre Therapeutics shares in Q4 2024, an estimated $17.6M.
  • Avoro Capital Advisors first reported a position in Spyre Therapeutics in Q2 2023 and held it in 6 quarters.
  • Avoro Capital Advisors's Spyre Therapeutics position peaked at $69.8M in Q1 2024.
  • 131 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2024.

Based on Avoro Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.